Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...

The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the Netherlands) said FDA extended by three months its review of an NDA for Plenvu (NER1006) for bowel...

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) added $6.02 (34%) to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix Pharmaceuticals gastroenterology business for about $10 billion. The reports named...

Valeant launched an oral formulation of Relistor methylnaltrexone in the U.S. to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The wholesale acquisition cost (WAC) for a 150 mg tablet is $16.67....

Pharming will pay Valeant $60 million up front and up to $65 million in sales milestones to reacquire North American commercialization rights to Ruconest conestat alfa. The recombinant human C1 esterase inhibitor is approved in...